Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

ConferenceLeqvioEntrestoPositive

AI Analysis

Summary

Novartis will present data from 10 abstracts at the 2026 ESC Congress showcasing its cardiovascular portfolio including foundational medicines Leqvio and Entresto, along with investigational therapies. The presentation reinforces the company's commitment to addressing unmet cardiovascular treatment needs.

Importance:4/10

Sentiment:

0.30

cardiovascularESC Congress 2026data presentationportfolio update

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on August 19, 2026 5:15 AM

Read Original